Assessing Inherited Markers of Metabolic Syndrome in the Young
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Endocrine, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 35 |
| Updated: | 2/10/2017 |
| Start Date: | February 2007 |
| End Date: | December 2016 |
The AIMM Young study is a collaboration between Children's National Medical Center (CNMC)
and colleges/universities nationwide--currently including Howard University (HU), East
Carolina University (ECU), and University of Massachusetts, Amherst (U Mass). This study
obtains a variety of baseline measures (such as serum biomarkers related to metabolic
syndrome, anthropometrics, muscle strength, and fitness testing) along with genetic
information from healthy college-age (18-35 years) young adults in efforts to identify
phenotype-genotype associations that may predispose individuals to developing metabolic
syndrome, type 2 diabetes, and/or related diseases such as obesity.
We hypothesized that certain genetic variations will be protective against metabolic
syndrome, while others will show a strong correlation with specific components of metabolic
syndrome disease. We expect that the study of "pre-symptomatic," young individuals will
facilitate the identification of genetic risk loci for metabolic syndrome and type 2
diabetes. Younger populations typically have less confounding variables, and this
facilitates normalizing of metabolic syndrome features and environment/lifestyle.
Additionally, young subjects can provide more robust longitudinal data, and be recruited
into subsequent interventions to reverse the trend towards metabolic syndrome, rather than
the more difficult task of reversing type 2 diabetes in older populations. The data
collected will be stratified according to gender, age, ethnicity, genotype, and other
phenotypic measures to determine how these factors influence disease risk.
and colleges/universities nationwide--currently including Howard University (HU), East
Carolina University (ECU), and University of Massachusetts, Amherst (U Mass). This study
obtains a variety of baseline measures (such as serum biomarkers related to metabolic
syndrome, anthropometrics, muscle strength, and fitness testing) along with genetic
information from healthy college-age (18-35 years) young adults in efforts to identify
phenotype-genotype associations that may predispose individuals to developing metabolic
syndrome, type 2 diabetes, and/or related diseases such as obesity.
We hypothesized that certain genetic variations will be protective against metabolic
syndrome, while others will show a strong correlation with specific components of metabolic
syndrome disease. We expect that the study of "pre-symptomatic," young individuals will
facilitate the identification of genetic risk loci for metabolic syndrome and type 2
diabetes. Younger populations typically have less confounding variables, and this
facilitates normalizing of metabolic syndrome features and environment/lifestyle.
Additionally, young subjects can provide more robust longitudinal data, and be recruited
into subsequent interventions to reverse the trend towards metabolic syndrome, rather than
the more difficult task of reversing type 2 diabetes in older populations. The data
collected will be stratified according to gender, age, ethnicity, genotype, and other
phenotypic measures to determine how these factors influence disease risk.
Inclusion Criteria:
- between the ages of 18 and 35 years
- post-puberty
- willing and able to provide informed consent
- stable medical and psychosocial status providing a high likelihood of follow-up and
compliance with study protocol
- all ethnic backgrounds will be included in this study.
Exclusion Criteria:
- evidence of clinically relevant systemic disease associated with disorders of glucose
metabolism
- chronic use of glucocorticoid or appetite suppressants
- concomitant use of drugs known to alter glucose metabolism (i.e., metformin,
thiazolidinediones, sulfonylurea receptor agonists and inhibitors of alpha-glucoside
hydrolase) or other medications known to alter blood levels being tested in this
study
- inability to provide the requested fasting blood sample
- pregnancy
- menopause
- alcohol dependency (as determined by CAGE screening questionnaire); (8) inability to
provide informed consent
- previous diagnosis or treatment for any hematologic-oncologic disorder
- history or current treatment for an eating disorder
- current treatment for weight loss
- history of bariatric surgery
- history of neurosurgical procedure
- participation in another clinical trial involving an investigational drug
- history of psychiatric disorder, which in the opinion of the investigator would
affect the conduct of the proposed trial
- age younger than 18 or older than 35 at the time of recruitment
- weight that exceeds the capacity of equipment used for weight measurements.
We found this trial at
1
site
111 Michigan Ave NW
Washington, District of Columbia
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
Click here to add this to my saved trials
